JB Chemicals & Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
JBCHEPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.3 pts less than Nifty Smallcap 250 and 0.9 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
JB Chemicals reported standalone revenue of ₹3,88,989 lakhs for FY26, up 4.5% from ₹3,72,292 lakhs in FY25. Standalone PAT grew 3.3% to ₹67,410 lakhs from ₹65,254 lakhs. Consolidated revenue was ₹4,14,779 lakhs (up 5.9%) with PAT at ₹70,947 lakhs (up 7.6%). The auditor Deloitte Haskins & Sells LLP issued an unmodified (clean) opinion on both standalone and consolidated results. Exceptional items of ₹2,718 lakhs were recorded, comprising severance compensation of ₹1,873 lakhs for distribution network restructuring and ₹845 lakhs due to New Labour Code impact on gratuity liability. The company declared a final dividend of ₹9.30 per share. Related party transactions for H2 FY26 were disclosed. The proposed merger with Torrent Pharmaceuticals has received shareholder and SEBI approval and is pending NCLT clearance.
Revenue and profit showed modest single-digit growth without major concerns. The exceptional items are one-time charges that will not recur. The ongoing Torrent Pharmaceuticals merger remains a key development for shareholders, as the company will cease to exist as a separate listed entity after NCLT approval.